solute carrier family 38 member 10Genealiases: PP1744 · SNAT10
Q-omics provides the consensus-scored SLC38A10 profile across patient tissues and cancer cell-line models. SLC38A10 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SLC38A10 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, SLC38A10 protein abundance shows 19,918 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, HNSC, and PDAC as cancer lineages where SLC38A10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC38A10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC38A10 survival associations across molecular data types. SLC38A10 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC38A10 RNA expression–survival associations across cancer types. High SLC38A10 expression shows unfavorable associations in KIRP, BLCA, LGG, ACC, UVM and KICH. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SLC38A10 RNA expression.
This table summarizes SLC38A10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC38A10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC38A10 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, KIRC, LIHC and LUAD. The HNSC box plot shows higher SLC38A10 RNA expression in tumor versus normal tissue (log2 FC = +0.845, t-test p < 0.001).
This table shows molecular features associated with SLC38A10 in patient tissues and cancer cell lines. In patient samples, SLC38A10 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC38A10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
